Executive Team
Richard Peters, MD, PhD
Founder & Executive Chairman
Dr. Richard Peters has over 30 years of experience in the healthcare industry and academia. He also serves as Chairman of Board of the Pharming Group (EURONEXT: PHARM; NASDAQ: PHAR) and Aprea Therapeutics (NASDAQ: APRE); Lead Independent Director of Kineta (NASDAQ: KANT); and strategic advisor to Aura Biosciences (NASDAQ: AURA).
Prior to these roles, Dr. Peters served as the Global Head for the Rare Diseases business at Sanofi Genzyme, and CEO of two Nasdaq-listed biotechnology companies: Yumanity Therapeutics and Merrimack Pharmaceuticals. Earlier in his career, Dr. Peters held medical leadership positions at Amgen, Onyx Pharmaceuticals, Genzyme, and Sanofi, and is a founder of X4 Therapeutics and PIC Therapeutics. He has also served on the faculty at the Massachusetts General Hospital, served as editor for the journals SCIENCE and JAMA, and has published over 100 editorial and research articles.
Dr. Peters completed Internal Medicine training at the Massachusetts General Hospital and a Howard Hughes post-doctoral fellowship at Harvard Medical School; both in Boston, MA. Dr. Peters holds an M.D. Degree and a PhD. in Pharmacology from the Medical University of South Carolina, Charleston, South Carolina, and began his medical studies at the Universite Catholique de Louvain in Belgium prior to immigrating to the US.
Annie Partisano, PharmD, MS
SVP, Head of Operations
Angela (Annie) Partisano comes to TellBio with over 15 years of pharmaceutical industry experience in both pre-commercial and commercial companies. Previously, she was Vice President of Medical Operations at Kiniksa Pharmaceuticals, Ltd., where she was responsible for the operational growth of the Medical Affairs team. Prior to joining Kiniksa, Annie held several positions of increasing responsibility within the Medical Affairs team at Alnylam Pharmaceuticals where she helped build a world-class global medical affairs vision, strategy, and operational capability and supported the launch of two novel RNAi therapeutics. Earlier in her career, Annie held leadership positions within the Medical Affairs teams at Genzyme Corporation (Sanofi Genzyme) and Boehringer Ingelheim Pharmaceuticals, Inc.
During her professional career, Annie has been recognized for establishing industry leading Medical functions as well as top-tier Medical Affairs Post-PharmD Fellowship programs in the Boston area. In 2018, Annie was named one of the Healthcare Businesswomen’s Association (HBA) Rising Star for her noteworthy achievements within the pharmaceutical industry.
Annie received her Doctor of Pharmacy degree as well as her Master of Science (Regulatory Affairs) from Northeastern University and completed post-doctorate residencies at the University of Rochester and Purdue University/Eli Lilly.
BOARD OF DIRECTORS
Richard Peters, MD, PhD
Executive Chairman, TellBio
Chairman, Pharming Group
Chairman, Aprea Therapeutics
Director, Kineta
Gary Crocker, MBA
Director, TellBio
President, Crocker Ventures
Chairman, Merrimack Pharmaceuticals
Chairman, Nexus Spine
Bernard Peters, MIBS
Director, TellBio
Chief Financial Officer, Sloan
President, Sloan Flushmate
BOARD OF DIRECTORS
Richard Peters, MD, PhD
Executive Chairman, TellBio
Chairman, Pharming Group
Chairman, Aprea Therapeutics
Director, Kineta
Gary Crocker, MBA
Director, TellBio
President, Crocker Ventures
Chairman, Merrimack Pharmaceuticals
Chairman, Nexus Spine
Bernard Peters, MIBS
Director, TellBio
Chief Financial Officer, Sloan
President, Sloan Flushmate
Pritesh Gandhi, PharmD
Chief Executive Officer, TellBio
FOUNDERS
Richard Peters, MD, PhD
Executive Chairman, TellBio
Chairman, Pharming Group
Chairman, Aprea Therapeutics
Director, Kineta
Daniel Haber, MD, PhD
Director, Massachusetts General Hospital Cancer Center
Professor of Oncology, Harvard Medical School
Mehmet Toner, PhD
Co-Director, MGH Center for Engineering in Medicine & Surgery
Professor of Biomedical Engineering, Harvard Medical School
David Ting, MD
Associate Professor, Massachusetts General Hospital and Harvard Medical School
Associate Clinical Director for Innovation, Massachusetts General Hospital Cancer Center
Shyamala Maheswaran, PhD
Professor of Surgery, Harvard Medical School
Scientific Director, Massachusetts General Hospital Laboratory for CTC Innovation
Ravi Kapur, PhD
CEO, BendBio Inc.
President, Boston Nanotech Inc.